LadRx, formerly known as CytRx, will look for “strategic and financing alternatives,” the cancer biotech said Wednesday.
The Los Angeles biotech, listed on the over-the-counter market, said it initiated a process looking for a merger, strategic sale, up-listing to Nasdaq or other...
